Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.
about
Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammationNeed for a paradigm shift in therapeutic approaches to CNS injurySoluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice.A Case for Microtubule Vulnerability in Amyotrophic Lateral Sclerosis: Altered Dynamics During DiseaseDesign, power, and interpretation of studies in the standard murine model of ALSExendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosisElectrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS miceGlutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis modelsSmall-molecule activator of glutamate transporter EAAT2 translation provides neuroprotectionCarrell-Krusen Symposium invited lecture. Clinical trials in motor neuron diseases.What transgenic mice tell us about neurodegenerative disease.Complex genetics of amyotrophic lateral sclerosis.One universal common endpoint in mouse models of amyotrophic lateral sclerosis.A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?Progress in therapy development for amyotrophic lateral sclerosisInhibiting drug efflux transporters improves efficacy of ALS therapeuticsCurrent pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy.Neuroprotective Effect of Bexarotene in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.New considerations in the design of clinical trials for amyotrophic lateral sclerosisA natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis.Randomized control trials in ALS: lessons learned.Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future.Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies.Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis.Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights.Decline in daily running distance presages disease onset in a mouse model of ALS.ALS drug development: reflections from the past and a way forwardALS Pathogenesis and Therapeutic Approaches: The Role of Mesenchymal Stem Cells and Extracellular VesiclesMoving forward in clinical trials for ALS: motor neurons lead the way please.Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis.A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.Potential new complication in drug therapy development for amyotrophic lateral sclerosis.Interaction of high concentrations of riluzole with recombinant skeletal muscle sodium channels and adult-type nicotinic receptor channels.Chronic inhibitory effect of riluzole on trophic factor production.Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.Current and emerging treatments for amyotrophic lateral sclerosis.Tardive decrease of astrocytic glutamate transporter protein in transgenic mice with ALS-linked mutant SOD1.Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis.Pre- and postsynaptic mechanisms underlying inhibition of hypoglossal motor neuron excitability by riluzole.Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
P2860
Q25256714-68B0C3B2-3ED4-4BF3-B974-FE6253C3A9FEQ27025042-78C21BC9-5BF1-4A3E-BA9D-40B26044F6B3Q27319831-20F32630-4B0A-4AD5-A14E-186B28DCC73EQ28079299-5B0306D6-7172-42A0-806E-1719934ED71AQ28268686-3BD509FC-1926-46BA-B7CA-ED702A080003Q28481242-76757057-F0C3-4FF7-953F-46B450F51669Q28533705-D74E3F7E-46BD-4A7C-9DF3-0ED7D4E6E98BQ28572282-BAC2C6B4-ADA5-4524-868B-50C8E6E93AD6Q30573062-79B9A4D0-5D3E-4518-9002-43A54B0FCF4AQ33586412-062E1784-51E6-481E-9A13-923CE18E44EAQ33843472-2D1797C7-C479-463A-8E5E-44AD17F5433EQ33910597-57DBF1C9-7490-417D-8097-B7A71CBFBE01Q33936763-C66A8002-4783-472B-859D-A06657686B6EQ34104378-1EB02219-6519-4DDB-9D7A-9804D509381EQ34640800-6DE3BA3D-3F6E-41AF-9A9A-DC89BD1A6215Q34824777-29DCC37A-B2D2-4D3C-AB14-37A77A74536BQ35753380-CC373FC3-47A3-4804-B753-C6805EE704A5Q35802822-781DE307-EB34-4258-80DC-215CBC3E2BDCQ35910744-6E64958D-BB5B-43A8-91A1-115775A1FA18Q35923499-51166299-8061-4046-A801-7F5E61A8DC36Q35932089-4C83D2FC-B170-4FBE-80F6-34C96BB728EEQ36314443-D62CFCF0-2A56-43AA-A49D-1C052687E9B2Q36419592-58167ED1-AFBC-49B0-974C-A05A810BFA4EQ36866600-829BF0D9-9283-4B6C-A749-AF8A90E6AD8FQ37206683-5AB65578-A960-4F79-B52C-78348394209AQ37251795-F89C8603-0C6F-4A82-8B64-F821884CB1BEQ37329513-62B23F02-A4A2-4E29-B4BE-D48D76A018FEQ37712624-8E76863A-8FF8-4F4A-96C9-A6D9AA68E64CQ38156505-8855FF00-7AF8-4FCA-B43E-815ED06D0CD7Q38452263-090B0869-F947-4802-99D0-3C61A86AC707Q38573829-0706E007-28A8-42E0-AC14-03087926A0B3Q38881707-F6F77CD0-5208-4FDC-9F05-C0F8B5079EA2Q40699967-2E7F1F2F-127B-4149-8A6B-97DEFEACEA9DQ41464979-1FBF83DD-AB8D-4067-9120-10702E2C6C92Q42164065-BFBD7457-1D0D-4FA5-B929-7CB9F8D30638Q42685032-55540B5E-5046-45F7-B1ED-F9F884914A31Q44142407-0EAA6773-2A6B-45A9-8ECC-A9BC7E7EE9C9Q44187182-8E4CED4A-EFA6-4D69-A733-6A91B7CD1161Q44652546-86BD4D1B-6C55-4914-BEE2-E7791A83F398Q44726519-70EB95B6-56B5-40F0-B3BA-F512F62C572B
P2860
Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Riluzole preserves motor funct ...... amyotrophic lateral sclerosis.
@en
Riluzole preserves motor funct ...... amyotrophic lateral sclerosis.
@nl
type
label
Riluzole preserves motor funct ...... amyotrophic lateral sclerosis.
@en
Riluzole preserves motor funct ...... amyotrophic lateral sclerosis.
@nl
prefLabel
Riluzole preserves motor funct ...... amyotrophic lateral sclerosis.
@en
Riluzole preserves motor funct ...... amyotrophic lateral sclerosis.
@nl
P2093
P356
P1433
P1476
Riluzole preserves motor funct ...... amyotrophic lateral sclerosis.
@en
P2093
P356
10.1212/WNL.50.1.62
P407
P577
1998-01-01T00:00:00Z